"Designing Growth Strategies is in our DNA"

Vancomycin-Resistant Staphylococcus aureus (VRSA) Drugs Market Size, Share and Global Trend By Product (Linezolid, Tigecycline, Daptomycin, Telavancin, Ceftaroline, Quinupristin, Dalfopristin, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2024-2032

Region : Global | Report ID: FBI100846 | Status : Ongoing

 

KEY MARKET INSIGHTS

The human body is a host of a variety of microbial flora. One among them is Staphylococcus aureus, a gram-positive bacterium, which is most commonly found on the skin as well as nasal passages of humans. According to the Department of Health, 20% of the human population is always colonized with Staphylococcus aureus. Being a facultative anaerobe, it can cause respiratory diseases, skin illness, and food poisoning. Apart from a Staph infection, it is also the common causative agent for illness such as boils, impetigo, pimples, abscesses and certain serious diseases such as pneumonia, meningitis, osteomyelitis, sepsis, and others.

According to the Health Research Funding Organization, there are 19,000 deaths worldwide due to Staph infection every year. According to Centre of Disease Control and Prevention, there were 13 cases in 4 states of U.S., during 2002-2013. In due course of time, the species of Staphylococcus aureus have developed resistance to many of the antimicrobial drugs. For example, MRSA, a class of Staphylococcus aureus which are resistant to Methicillin.

To gain extensive insights into the market, Request for Customization

Similarly, vancomycin-resistant Staphylococcus aureus is one of the strains of Staphylococcus aureus resistant to the antibiotic vancomycin or glycopeptides. There are three types of vancomycin-resistant Staphylococcus aureus namely high-level VRSA, vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA). According to the Texas Department of State Health Services, there were 13 cases of VISA in 2016 in Texas.

The growth in global vancomycin-resistant Staphylococcus aureus drugs market is being driven by an increased incidence of diseases caused by VRSA, poor sanitation which in turn increases the risk of hospital-acquired infection. In addition to that, increased awareness program and government funding in research and developments of new drugs are expected to drive the market growth.

Certain factors such as the increased usage of generic alternatives especially due to the loss of patents, the short lifecycle of the drugs and the anticipated slower growth due to the increasing maturity of the market are expected to limit the growth of the global vancomycin-resistant Staphylococcus aureus (VRSA) drugs market.

Key Players Covered


Some of the major companies that are present in the global Vancomycin-Resistant Staphylococcus aureus (VRSA) Drugs market are GlaxoSmithKline, AstraZeneca Plc, Cubist Pharmaceutical, Forest Laboratories, Debiopharm International, iNtRON Biotechnology, Crystal Genomics, Wockhardt Limited, Destiny Pharma Ltd, Therapeutic Systems Research Laboratories Inc., and others.

SEGMENTATION


























SEGMENTATION


 DETAILS


By Product


· Linezolid

· Tigecycline

· Daptomycin

· Telavancin

· Ceftaroline

· Quinupristin

· Dalfopristin

· Others


By Route of Administration


· Oral

· Parenteral


By Distribution Channel


· Hospital Pharmacies

· Retail Pharmacies

· Online Pharmacies

· Others


By Geography


· North America (the USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)


 

Among the segmentation, Linezolid in the drug class segment is projected to hold a considerable share of the global Vancomycin-Resistant Staphylococcus aureus (VRSA) drugs market due to higher adoption of linezolid and the ability of the linezolid to able to fight against a number of gram-positive bacterial infections.

 Key Insights






  • Epidemiological Analysis and Prevalence of Diseases Caused by VRSA for Key Countries
  • Pipeline Analysis
  • Recent Industry Developments such as Partnerships, Mergers, and Acquisitions
  • Patent Analysis
  • New Product Launches

Regional Analysis


North America is anticipated to hold a considerable share of the global vancomycin-resistant Staphylococcus aureus (VRSA) drugs market owing to increasing incidences of VRSA infections, increasing R&D initiatives and the increasing demand for novel therapeutics. The Asia Pacific holds potential for Vancomycin-Resistant Staphylococcus aureus (VRSA) Drugs owing to the rise in prevalence of chronic diseases and increasing development of healthcare infrastructure. One of the other key contributors to the growth in this region is the increasing number of pharmaceutical manufacturers and also the high adoption of generic medications.

Key Industry Developments



  • In February 2019, scientists at Rutgers University discovered two genes that enable infections such as VRSA resistant to treatment
  • In November 2018, Roivant Sciences and iNtRON Bio entered into a licensing deal for a novel anti- superbugs biologic called SAL200, that will enable the treatment of VRSA infections. SAL200 in its pre-clinical studies showed bacterial activity against the pathogen of VRSA.

  • Ongoing
  • 2023
  • 2019-2022

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $6850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

uniliver
Pfizer
abbvie
iqvia
Lek

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X